On Oct. 27, 2021, Novavax announced the completion of its rolling regulatory submission to the U.K. Medicines and Healthcare products Regulatory Agency for authorization of its COVID-19 vaccine candidate. The company’s application for Conditional Marketing Authorization marked the first submission for authorization of a protein-based COVID-19 vaccine in the UK.